Lupin Gets USFDA Approval for Generic Pulmonary Hypertension Drug
By Rediff Money Desk, NEWDELHI Nov 02, 2023 14:19
Lupin receives USFDA approval to market generic Selexipag for injection, a treatment for pulmonary arterial hypertension. The drug will be manufactured at the company's Nagpur facility.
![Lupin Gets USFDA Approval for Generic Pulmonary Hypertension Drug](https://im.rediff.com/money/2019/nov/12lupin.jpg)
New Delhi, Nov 2 (PTI) Drug maker Lupin on Thursday said it has received approval from the US health regulator to market generic medication to treat pulmonary arterial hypertension.
It has received tentative approval from the US Food and Drug Administration (USFDA) for Selexipag for injection, Lupin said in a regulatory filing.
The company's product is a generic version of Actelion Pharmaceuticals US, Inc.'s Uptravi for injection.
Lupin said the product would be manufactured at its Nagpur facility.
The product sales for Selexipag franchise in the US stood at USD 1,104 million for the year ended December 2022.
It has received tentative approval from the US Food and Drug Administration (USFDA) for Selexipag for injection, Lupin said in a regulatory filing.
The company's product is a generic version of Actelion Pharmaceuticals US, Inc.'s Uptravi for injection.
Lupin said the product would be manufactured at its Nagpur facility.
The product sales for Selexipag franchise in the US stood at USD 1,104 million for the year ended December 2022.
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- GTL Infrastructure
- 2.93 ( -4.87)
- 226206286
- IFL Enterprises
- 1.30 (+ 4.84)
- 81461564
- Vodafone Idea L
- 16.79 (+ 0.66)
- 67447398
- NCL Research
- 0.95 ( -4.04)
- 31996628
- Franklin Industries
- 3.73 (+ 3.32)
- 21511209
MORE NEWS
![Cipla Faces Rs...](https://im.rediff.com/80-80/money/2020/oct/01tax.jpg)
Cipla Faces Rs 773 Crore I-T Demand: Details -...
Cipla receives a Rs 773.44 crore demand notice from the income tax department for...
![EV Segment Growth...](https://im.rediff.com/80-80/money/2023/jun/19ev.jpg)
EV Segment Growth Needs Long-Term Policy...
Lohia CEO Ayush Lohia emphasizes the need for long-term policy support, including FAME...
![Gold Price Rises...](https://im.rediff.com/80-80/money/2015/jul/01gold.jpg)
Gold Price Rises Rs 550, Silver Jumps Rs 400 |...
Gold prices surged by Rs 550 to Rs 75,700 per 10 grams on Tuesday, driven by strong...